LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

LLY

1,014.52

-1.97%↓

JNJ

202.07

-1.79%↓

ABBV

228.32

-0.87%↓

UNH

331.69

-2.2%↓

AZN

90.21

-0.75%↓

Search

Lisata Therapeutics

Abierto

2.02 7.45

Resumen

Variación precio

24h

Actual

Mínimo

1.85

Máximo

2.06

Métricas clave

By Trading Economics

Empleados

26

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-5M

15M

Apertura anterior

-5.43

Cierre anterior

2.02

Lisata Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 dic 2025, 23:21 UTC

Ganancias
Adquisiciones, fusiones, absorciones

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dic 2025, 23:14 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dic 2025, 22:01 UTC

Principales Movimientos del Mercado

Costco Wholesale Reports Higher Monthly Sales

3 dic 2025, 21:38 UTC

Ganancias

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dic 2025, 23:59 UTC

Charlas de Mercado

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dic 2025, 23:13 UTC

Charlas de Mercado

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dic 2025, 23:10 UTC

Ganancias

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dic 2025, 23:08 UTC

Charlas de Mercado

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dic 2025, 23:06 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dic 2025, 22:45 UTC

Charlas de Mercado

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dic 2025, 22:20 UTC

Ganancias

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dic 2025, 22:19 UTC

Ganancias

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dic 2025, 22:17 UTC

Ganancias

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dic 2025, 22:16 UTC

Ganancias

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dic 2025, 22:15 UTC

Ganancias

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dic 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dic 2025, 22:09 UTC

Adquisiciones, fusiones, absorciones

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

3 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 dic 2025, 21:49 UTC

Ganancias

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:23 UTC

Ganancias

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dic 2025, 21:19 UTC

Ganancias

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:06 UTC

Ganancias

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:04 UTC

Ganancias

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dic 2025, 21:04 UTC

Ganancias

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dic 2025, 21:03 UTC

Ganancias

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparación entre iguales

Cambio de precio

Lisata Therapeutics Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Finanzas

$

Acerca de Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
help-icon Live chat